That the 100mg dose of IDX899 works as monotherapy is excellent news for two reasons:
1. The lower the dose, the better the tolerability will be when IDX899 is added to a standard treatment backbone such as Truvada.
2. The reason mentioned by Genisi (#msg-31929218): a lower dose has a smaller footprint, which facilitates co-formulation into a single pill with Truvada.
-- Still, I don’t think today’s news re the 100mg dose is what drove the share price yesterday because the data reported today were fully expected, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.